MLANA and cancer: First-generation peptide vaccines with non-mutant TAA, such as MAGE-A3, NY-ESO-1, tyrosinase, TRP-2, or MART-1 delivered with an adjuvant or pulsed on autologous or allogeneic DC, resulted in clinical responses in only a limited number of cancer patients [23, 44–46].